Stockwinners Market Radar for April 08, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:51 EDT McMahon sells TKO shares to Endeavor, TKO for $89.01 per share - TKO Group (TKO) disclosed that on April 4, Endeavor (EDR) entered into a stock purchase agreement with Vincent McMahon, pursuant to which Endeavor agreed to purchase 1,642,970 shares of class A common stock of TKO, held by McMahon, at a per share price of $89.01 for an aggregate amount of $146.2M. On April 7, TKO entered into a stock purchase agreement with the McMahon, pursuant to which TKO agreed to purchase 1,853,724 shares of common stock of TKO held by McMahon at a per share price of $89.01 for an aggregate amount of $165M. TKO intends to fund the share repurchase with approximately $150M of borrowings under its revolving credit facility.

20:49 EDT Cathie Wood's ARK Investment bought 97K shares of Teladoc today

19:50 EDT Allarity Therapeutics Inc trading halted, news pending

18:51 EDT Rocket Lab awarded $14.49M task order by the U.S. Space Force - Rocket Lab announced it has been awarded a $14.49M task order by the U.S. Space Force to launch an Electron mission from Launch Complex 2. The mission, called Space Test Program-30 falls under the Space Systems Command Assured Access to Space organization and is part of Orbital Services Program-4.

18:14 EDT Cadrenal Therapeutics' tecarfarin receives FDA orphan designation - According to a post on the FDA's website, Cadrenal Therapeutics' tecarfarin received orphan designation. Reference Link

18:08 EDT Soligenix prevention against Marburg marburgvirus gets FDA orphan designation - According to a post on the FDA's wesbite, Soligenix's prevention against Marburg marburgvirus infection received orphan designation. Reference Link

18:04 EDT Candel Therapeutics' treatment of pancreatic cancer receives orphan designation - According to a post on the FDA's website, Candel Therapeutics' treatment of pancreatic cancer received orphan designation. Reference Link

17:28 EDT Lockheed Martin awarded $271.3M U.S. Defense Department contract modification - Lockheed Martin Rotary and Mission Systems is being awarded a $271,286,879 modification to previously awarded contract, HQ085121C0001 under Foreign Military Sales Case JA-P-NCO. This modification includes cost-plus-incentive-fee and cost-plus-fixed-fee contract line items. The total value of the contract is increased by $271,856,809 from $674,477,035 to $946,333,844.

17:18 EDT Maxeon Solar falls 9% to $2.49 after below-consensus Q4 and Q1 outlook

17:03 EDT Casi Pharmaceuticals discloses development relating to dispute with Juventas - Casi Pharmaceuticals reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. Reference Link

17:00 EDT Stratasys names Amir Kleiner as new COO - Stratasys "announced the appointment of Amir Kleiner as Chief Operating Officer. The 12-year Stratasys veteran will lead the company's Global Operations, MIS, and Quality team, while continuing to manage the Customer Success team. The appointment is set to strengthen the connection between the Customer Success organization and the Operations and Supply Chain divisions."

16:45 EDT Penske Automotive expands retail automotive presence to Australia - The company stated: "Penske Automotive intends to expand its retail automotive operations into Australia by acquiring two Porsche dealerships along with a Ducati motorcycle dealership in Melbourne, Australia. The Company has signed an agreement to acquire Porsche Centre Brighton, Porsche Centre Doncaster and Ducati Melbourne West. The Brighton dealership, which is located approximately 20 minutes from central Melbourne, opened in March 2009 and has been serving the Porsche community in Melbourne for nearly 15 years. The Doncaster dealership is the newest official Porsche Centre located in the high-growth northeast Melbourne suburbs."

16:41 EDT Vincerx: progress for VIP236 and VIP943 for solid tumors presented at AACR - Vincerx Pharma presented positive preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research AACR Annual Meeting 2024. "The positive preliminary data we've reported for VIP236 and VIP943, coupled with preclinical findings leveraging our VersAptx platform to improve the efficacy of TRODELVY and ENHERTU, two marketed ADCs, underscore the power of our platform approach for hematologic malignancies and solid tumors," said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. "The early VIP236 data demonstrated positive clinical activity, including tumor reductions. This represents significant promise for patients who have exhausted standard anticancer therapy options with many different tumor types, including tumors not usually responsive to camptothecin-derived therapies. Dose escalation continues in the VIP236 and VIP943 first-in-human studies. As we advance into higher dose levels, we look forward to sharing more clinical data for VIP236 later this summer and for VIP943 on or around the 2024 European Hematology Association annual meeting."

16:39 EDT Asur reports March passenger traffic up 6.6% y/y - Asur announced that passenger traffic for March 2024 reached a total of 6.5M passengers, representing an increase of 6.6% compared to March 2023. Passenger traffic presented year-on-year increases of 3.4% in Mexico, 16.0% in Puerto Rico and 9.4% in Colombia. Passenger traffic growth in Mexico was driven by an 11.1% increase in international traffic that offset a 6.83% decrease in domestic traffic. Puerto Rico reported growth in domestic and international traffic, 14.9% and 27.1%, respectively. Passenger traffic in Colombia reported growth in domestic and international traffic of 3.6% and 37.7%, respectively.

16:36 EDT Theratechnologies announces data presentation of SORT1+ technology at AACR - Theratechnologies presented preclinical data that highlight the versatility and flexibility of the Company's SORT1+ Technology platform. In a poster session at the 2024 annual meeting of the American Association for Cancer Research AACR in San Diego, Calif., researchers reported that Theratechnologies' investigational camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer CRC and triple-negative breast cancer TNBC xenograft models. The study also demonstrated synergistic anti-tumor efficacy and good tolerability with the combination of two peptide drug conjugates with different payloads. "The preclinical data presented at AACR add to the sizeable body of evidence supporting the potential utility of the SORT1+ Technology platform as an engine for the development of novel peptide-drug conjugates to treat various types of cancer," said Christian Marsolais Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies. "In addition to our lead peptide-drug conjugate, sudocetaxel zendusortide, these latest data highlight the promising tolerability and anti-tumor effects of our investigational camptothecin-peptide conjugates, further demonstrating the versatility and flexibility of the platform. We welcome discussions with potential partners who are interested in the further development of these innovative therapies."

16:33 EDT Angi appoints Jeff Kip CEO - Angi announced the appointment of Angi president and long-time IAC and Angi executive Jeff Kip to CEO, succeeding Joey Levin. As CEO, Kip will lead Angi's executive team, overseeing strategy and daily management of the company. Levin, CEO of IAC, will continue as chairman of the Angi board. All changes are effective immediately. "Through multiple roles, Jeff Kip has been a student of the Angi business, first as CFO of IAC, then serving as CEO of Angi's International business for nearly eight years and most recently as President of Angi," said Joey Levin, CEO of IAC and Chairman of Angi. "During his tenure with Angi, he engineered the integration of multiple different product and technology platforms across six countries, driving the International business to healthy growth with expanding margins - an inspiring blueprint for Angi's future." Kip has served as Angi's President since November 2023 and as CEO of Angi's international business since 2016. Previously he served as CFO at IAC. Prior to joining IAC, Kip spent six years as CFO at Panera Bread Company, holding a number of leadership roles over the course of his nearly decade-long tenure. Prior to Panera, Kip held positions at investment banking firms UBS and Goldman Sachs.

16:31 EDT Harmonic CEO Patrick Harshman to retire, Nimrod Ben-Natan to succeed - Harmonic announced that Patrick Harshman will retire as President and CEO, effective June 11. Nimrod Ben-Natan, currently Senior Vice President and General Manager of Harmonic's Broadband business, has been appointed as Harshman's successor by Harmonic's Board of Directors. Harshman will work with the Board and Ben-Natan to ensure a smooth transition. Ben-Natan joined Harmonic in 1996 as a software engineer to design and develop its first-generation video transmission platform. He has led Harmonic's Broadband business as Senior Vice President and General Manager since 2012.

16:23 EDT Ashford Hospitality sees Q1 occupancy ~67% - Ashford Hospitality Trust reported that the company expects to report Occupancy of approximately 67% for the first quarter of 2024 with Average Daily Rate of approximately $191 resulting in RevPAR of approximately $128. This Comparable RevPAR reflects an approximate decrease of 1% compared to the first quarter of 2023. Additionally, for the month of January 2024, Comparable RevPAR increased approximately 2.1% versus January 2023. For the month of February 2024, Comparable RevPAR decreased approximately 0.3% versus February 2023. For the month of March 2024, Comparable RevPAR decreased approximately 3.7% versus March 2023. "Ashford Trust continues to benefit from increased corporate and group demand. While our March operating results were soft, which we directly attribute to the Easter Holiday shift, we expect to see a marked improvement for April," commented Rob Hays, Ashford Trust's President and CEO. "Additionally, we remain focused on paying off our strategic corporate financing and have made meaningful progress towards our deleveraging plan. As we look to the remainder of 2024, we believe our high-quality, geographically diverse portfolio remains well-positioned to outperform."

16:20 EDT Allbirds gets Nasdaq notice of non-compliance with Nasdaq minmum bid price rule - Allbirds announced that on April 2 Allbirds received notice from The Nasdaq Stock Marke that Allbirds is no longer in compliance with Nasdaq's Listing Rule 5450 a1 because the closing bid price of the Allbirds' Class A common stock has fallen below $1.00 per share for 30 consecutive days. Allbirds' Class A common stock will continue to be listed and traded on the Nasdaq, subject to Allbirds' compliance with other Nasdaq continued listing standards, and operations are not affected by receipt of the Notice.

16:17 EDT Norwegian Cruise Line announces strategic long-term fleet expansion - Norwegian Cruise Line Holdings unveiled a new build order in its history-a total of eight state-of-the-art vessels, representing nearly 25,000 additional berths, with new classes of ships for each of its three award-winning brands-and the construction of a multi-ship pier at Great Stirrup Cay, the company's private island destination in the Bahamas and its top-rated Caribbean port of call. This decade-long strategy enhances its product offering, guest experiences, and operational infrastructure, supporting the company's sustained leadership in delivering innovative cruise vacations. The new ship orders across all three brands are scheduled for delivery over a ten-year period, between 2026 and 2036. Following the delivery of four Prima-Plus class ships from 2025 through 2028, Norwegian Cruise Line is expected to take delivery of four approximately 200,000-gross-ton ships, each with a capacity of nearly 5,000 guests, in 2030, 2032, 2034 and 2036, which are subject to financing1. Building on the success of its Allura Class ships, the last one being delivered in 2025, Oceania Cruises is scheduled to take delivery of two 86,000-gross-ton ships, each with a capacity of 1,450 guests in 2027 and 2029. Lastly, following the award-winning Explorer Class ships, Regent Seven Seas Cruises is scheduled to take delivery of two 77,000-gross-ton ships, each with a capacity of 850 guests, in 2026 and 2029. Details regarding the ships' amenities, staterooms, dining, recreational, efficiency, sustainability and other features will be announced in the coming months.

16:15 EDT Brookdale Senior Living reports March occupancy - March 2024 Observations: March's weighted average occupancy increased 180 basis points year-over-year to 77.9%, remaining flat sequentially to February's weighted average occupancy. March's increase over the prior year March reflected a continued monthly trend of accelerated year-over-year improvement in the first quarter, and represents the company's twenty-ninth consecutive month of year-over-year weighted average occupancy growth. Demonstrating an improvement from normal pre-pandemic seasonality, first quarter 2024 weighted average occupancy decreased (50) basis points compared to the fourth quarter 2023.

16:14 EDT Sonoco, Engie announce 140 megawatt virtual power purchase agreement - Sonoco Products Company and Engie North America announced that they have entered into a Virtual Power Purchase Agreement, VPPA, for production from Engie's Big Sampson Wind Project, a wind power project currently under construction in Crockett County, Texas. Under the VPPA and subject to certain conditions, Sonoco and Engie have agreed to contract for an estimated 140 megawatts of electricity per year, representing approximately 48% of Sonoco's U.S. electricity consumption in 2025 and approximately 52% of the expected output capacity of Big Sampson, for a term of 15 years commencing upon Big Sampson's entry into commercial operation.

16:12 EDT ShockWave Medical data confirm consistent 'real-world' outcomes - Shockwave Medical announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results to three years. These findings confirm the positive, 'real-world' outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina. ...The primary effectiveness endpoint for the study was the percentage of patients experiencing improvement in their symptoms of angina defined as a reduction in Canadian Cardiovascular Society grade at six months compared with baseline. The primary safety endpoints were the rate of device- and/or procedure-related periprocedural serious adverse events and major adverse cardiac events up to 30 days post implant. "Results from the REDUCER-I study continue to demonstrate the safety and effectiveness of Shockwave Coronary Sinus Reducer as a novel therapy for refractory angina," said Dr. Verheye. "We observed consistent reduction in symptoms of refractory angina and improvements in quality of life, results which align with those from the COSIRA study, previously published in The New England Journal of Medicine, in a challenging patient cohort characterized by high rates of cardiovascular risk factors and coexisting comorbidities for whom there have historically been no other treatment options."

16:08 EDT Kineta presents data from Phase 1/2 VISTA-101 clinical trial at AACR - Kineta announced at the American Association for Cancer Research AACR in San Diego, CA an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA pembrolizumab , in patients with advanced solid tumors. KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab. KVA12123 was well tolerated with no dose limiting toxicities DLT or cytokine related adverse events at any dose level. "We are pleased to present our progress on the VISTA-101 clinical trial at AACR this year, with the initial clinical response data and the durability of patient benefit emerging from the study. The safety profile of KVA12123 to date has been remarkable in the monotherapy as well as combotherapy cohorts, supporting advancement to the final monotherapy dosing cohort of KVA12123 and reaching the estimated optimal therapeutic dose," said Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta. "Initial read-outs demonstrated that KVA12123 is not only safe but exhibits potential clinical benefit for some patients as either monotherapy or combotherapy and may offer patients a novel approach to address immunosuppression in the tumor microenvironment and better manage solid tumor cancers." In February 2024, the company announced that it is pursuing strategic alternatives to maximize shareholder value due to certain investors indicating they will not fulfill their April 2024 funding obligation in the previously disclosed private placement financing. As a result, the company has suspended new patient enrollment into the Phase 1/2 VISTA-101 trial and will not be recruiting patients into either the sixth cohort in the monotherapy arm or the third cohort in the combination therapy arm. Patients currently enrolled in the trial will be permitted to continue to participate.

16:06 EDT Methode Electronics announces retirement of CFO Ronald Tsoumas - Methode Electronics announced that Ronald Tsoumas, Chief Financial Officer, is retiring from the company effective July 12, 2024, following the filing of Methode's FY24 annual report. The company has begun a search process with the assistance of a leading executive search firm to identify Tsoumas' permanent successor. Following Tsoumas' retirement and provided a permanent successor has not been hired, the company plans to appoint David Rawden, a director at consulting firm AlixPartners, as interim CFO until a permanent successor is identified. Rawden has held multiple CFO and interim CFO positions at both publicly traded and private companies. He brings over 25 years of finance, accounting and administrative experience and is a certified public accountant.

16:04 EDT Bloom Energy to receive up to $75M in federal tax credits for Fremont plant - The company states: "Bloom Energy was recently awarded up to $75M in tax credits by the Department of Energy, Department of Treasury, and the Internal Revenue Service under the Qualifying Advanced Energy Project 48C initiative. Bloom was selected for this award for its commitment to expand domestic manufacturing and fuel cell and electrolyzer production capacity at its multi-gigawatt Fremont, California manufacturing plant. At the heart of Bloom Energy's recently opened Fremont facility is the ability to manufacture high-efficiency fuel cell stacks, which serve as the foundational technology for the company's Energy Server(R) platform and Bloom Electrolyzer. The funding is part of the $4 billion in tax credits recently announced by the White House under the Qualifying Advanced Energy Project Tax Credit to accelerate domestic clean energy manufacturing and reduce greenhouse gas emissions at industrial facilities."

15:57 EDT Harley-Davidson ratifies new collective bargaining agreements with three unions - Harley-Davidson announced that the company has ratified new collective bargaining agreements with the three unions representing employees at the company's Wisconsin manufacturing facilities, namely the United Steelworkers Local 2-209 and the International Association of Machinists and Aerospace Workers Lodge 78 representing workers at the Menomonee Falls, WI facility, and the United Steelworkers Local 460 representing workers at the Tomahawk, WI facility. Harley-Davidson Chairman, President, and CEO, Jochen Zeitz said: "Today's announcement reinforces the strong and positive relationship between Harley-Davidson and the unions. I'd like to take this opportunity to thank both union and company representatives for their hard and most constructive work in achieving today's agreement."

12:36 EDT Better Choice Company trading halted, volatility trading pause

12:06 EDT Poseida: Phase 1 data supports potential of P-BCMA-ALLO1 therapy in MM - Poseida Therapeutics announced new data from a subset of patients in an ongoing Phase 1 study of its lead program, P-BCMA-ALLO1. Results showed that three of the five patients with relapsed/refractory multiple myeloma who had progressed following BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1. In addition, this investigational treatment was well-tolerated. These new Phase 1 study subgroup data and a new data analysis of different lymphodepletion regimens in patients treated with P-BCMA-ALLO1 for multiple myeloma or P-MUC1C-ALLO1 for solid tumors are being presented today in a poster session at the American Association for Cancer Research Annual Meeting 2024 in San Diego. The open-label, multicenter Phase 1 dose-escalation study in patients with relapsed/refractory multiple myeloma is assessing the safety and maximum tolerated dose of P-BCMA-ALLO1 (primary objective) and its anti-myeloma activity. Study participants were required to have received a prior proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody. Five study participants who had progressed on or following prior BCMA-targeting autologous CAR-T, T-cell engagers or both, and with ninety days post-P-BCMA-ALLO1 treatment follow-up, are presented in this poster. Key findings from the subgroup analysis showed that P-BCMA-ALLO1 was well tolerated with no dose-limiting toxicities, graft vs. host disease, or Grade 3 or greater cytokine release syndrome or immune effector cell neurotoxicity syndrome. The overall response rate in patients receiving P-BCMA-ALLO1 was 60%, with all three patients who achieved a clinical response experiencing a very good partial response. This included one patient who had previously received both teclistamab and an autologous CAR-T therapy and has maintained a response for more than four months.

12:04 EDT Avangrid, Statkraft enter virtual power purchase agreement - Avangrid and Statkraft announced the signing of a Virtual Power Purchase Agreement, establishing a new relationship between the two companies in the United States. Statkraft will receive Renewable Energy Certificates from Avangrid's 300 MW Streator Cayuga Ridge South Wind Farm in Illinois with this short term VPPA. This is the first agreement between the two companies in the U.S. market. Statkraft and Iberdrola, S.A., Avangrid's parent company, have a Power Purchase Agreement in place for energy produced at Iberdrola's Korytnica II wind farm in Poland.

12:02 EDT MiNK announces presentation of MiNK-215 data at AACR meeting - MiNK Therapeutics announced the presentation of data from MiNK-215, an investigational IL-15 armored fibroblast activation protein targeting CAR-iNKT cell therapy, at the American Association for Cancer Research Meeting in San Diego, CA. "MiNK-215 represents a novel cellular therapeutic to overcome the limitations of immune checkpoint blockade therapy. The data presented at AACR demonstrate MiNK-215's potential to effectively combat colorectal liver metastases, offering hope for patients who have exhausted conventional treatment options," said Dr. Jennifer Buell, President and CEO at MiNK. "Furthermore, these results accentuate MiNK-215's versatility and synergistic potential when paired with immunotherapies such as Agenus' botensilimab and balstilimab. This collaboration holds promise in bolstering the anti-tumor response, particularly in the formidable realm of microsatellite stable colorectal cancer." Human organoid models of CRC with liver metastases revealed that MiNK-215 exhibits potent anti-tumor activity through multiple mechanisms that include: Tumor stroma remodeling: MiNK-215 effectively remodels the tumor stroma, the supportive tissue surrounding the tumor to create a more favorable environment for immune cell infiltration and activity. Immune activation: By reprogramming the tumor microenvironment, MiNK-215 reduces the presence of immune-suppressive FAP expressing stellate cells and CXCL-12 expressing cells. Enhanced tumor killing: MiNK-215 recruits tumor-reactive T cells, pivotal in mounting an effective immune response against the tumor, ultimately leading to enhanced tumor eradication.

12:00 EDT Auna falls -8.8% - Auna is down -8.8%, or -80c to $8.30.

12:00 EDT Ducommun rises 15.8% - Ducommun is up 15.8%, or $7.66 to $56.23.

12:00 EDT Apartment Income REIT rises 22.6% - Apartment Income REIT is up 22.6%, or $7.08 to $38.43.

11:40 EDT Revolution Medicines announces publications on discovery of RMC-7977 - Revolution Medicines announced the publication of two peer-reviewed research papers in Nature. The first paper highlights the discovery and preclinical characterization of RMC-7977, a preclinical tool compound representative of a class of oral RAS(ON) multi-selective inhibitors, including the investigational drug candidate RMC-6236, that target multiple RAS variants. The second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC. This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe. Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer, PDAC and colorectal cancer. RAS G12 mutations, such as G12D, G12V and G12C, predominate in human cancers. Approved KRAS-targeted cancer therapies target only one particular RAS mutation, KRAS G12C. The first Nature paper describes RMC-7977, a RAS(ON) multi-selective inhibitor preclinical tool compound, which was designed to inhibit the full spectrum of oncogenic RAS mutations, including RAS codon 12 mutations as well as non-mutated wild-type RAS. RMC-7977 engages the intracellular chaperone cyclophilin A to form a binary complex that binds reversibly and with high affinity to RAS proteins that are in the active, GTP-bound or ON state. In preclinical studies, RMC-7977 demonstrated robust, durable anti-tumor activity at well-tolerated doses across a range of RAS-mutated NSCLC, PDAC and CRC models. Importantly, the preclinical study demonstrated that RAS(ON) multi-selective inhibitors, as represented by RMC-7977, have the potential to overcome some of the resistance mechanisms that have been shown to limit the clinical efficacy and durability of current KRAS(OFF) G12C-selective inhibitors, including adaptive signaling mechanisms mediated by activation of wild-type RAS. The second report describes research into the pharmacology and anti-tumor activity of the tool compound, RMC-7977, which was evaluated across a diverse range of preclinical PDAC models. Broad and pronounced anti-tumor activity was observed across various preclinical models following direct RAS inhibition by RMC-7977 at exposures that were well tolerated in vivo, providing a strong preclinical rationale for evaluating broad-spectrum RAS inhibition in the clinical PDAC setting. Furthermore, careful analysis of recognized clinical resistance mechanisms in a sophisticated model of PDAC treated with RMC-7977 revealed a promising combination treatment regimen that may be capable of countering monotherapy drug resistance. The investigational oral drug candidate RMC-6236 is a RAS(ON) multi-selective inhibitor designed to treat patients with cancers driven by a wide range of common RAS mutations. Revolution Medicines is currently evaluating RMC-6236 as monotherapy in a first-in-human trial in patients with advanced solid tumors harboring G12X, G13X, and Q61X mutations. Based on promising preliminary data in this trial, planning is underway to initiate pivotal studies of RMC-6236 as monotherapy in NSCLC and PDAC. RMC-6236 is also being evaluated in combination with pembrolizumab with or without chemotherapy in patients with advanced RAS-mutated solid tumors and in combination with RMC-6291, the company's investigational RAS(ON) G12C-selective inhibitor, for patients with advanced KRAS G12C-mutated solid tumors.

11:33 EDT Bristol Myers: Krazati plus cetuximab showed ORR of 34%, PFS of 6.9 months - Bristol Myers Squibb announced data from the cohorts of the Phase 1/ 2 KRYSTAL-1 study evaluating KRAZATI in combination with cetuximab for the treatment of patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer. These late breaking data will be featured in an oral presentation at the 2024 American Association for Cancer Research annual meeting on Monday, April 8 at 11:10 a.m. Pacific Time and will be highlighted as part of the meeting's official press program. The data will also be published simultaneously in Cancer Discovery. With a median follow up of 11.9 months in 94 patients, KRAZATI plus cetuximab demonstrated an objective response rate, the primary endpoint, of 34%, median progression-free survival of 6.9 months, and median overall survival of 15.9 months in pre-treated patients with KRASG12C-mutated locally advanced or metastatic CRC. The median duration of response was 5.8 months. Disease control was observed in 85% of patients. The safety profile for KRAZATI plus cetuximab was manageable and consistent with previous reports, and with the known safety profile of each drug individually. The company announced in February 2024 that the FDA had accepted a supplemental new drug application for KRAZATI in combination with cetuximab as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic CRC for priority review and assigned a Prescription Drug User Fee Act goal date of June 21, 2024.

10:36 EDT TSMC awarded $6.6B from Department of Commerce for Arizona plants - The U.S. Department of Commerce and TSMC Arizona Corporation, a subsidiary of Taiwan Semiconductor Manufacturing Company, signed a non-binding preliminary memorandum of terms to provide up to $6.6B in direct funding under the CHIPS and Science Act. The proposed funding would support TSMC's investment of more than $65B in three greenfield leading-edge fabs in Phoenix, Arizona. "After initially announcing two fabs in the U.S., TSMC Arizona is committing to build an additional third fab before the end of the decade. With this proposed funding, TSMC Arizona would be ensuring the formation of a scaled leading-edge cluster in Arizona, creating approximately 6,000 direct manufacturing jobs, more than 20,000 accumulated unique construction jobs, and tens of thousands of indirect jobs in this decade and bringing the most advanced process technology to the United States," Department of Commerce said in a statement.

10:13 EDT CoreRx completes acquisition of Societal CDMO - CoreRx, has completed its acquisition of Societal CDMO. CoreRx's tender offer to acquire all of the issued and outstanding shares of common stock of Societal CDMO, at a purchase price of $1.10 per Share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 2024 and was not further extended. The depositary and paying agent for the tender offer has advised CoreRx that, as of the expiration of the tender offer, a total of 102,588,622 Shares were validly tendered and not properly withdrawn, representing approximately 92.8% of the issued and outstanding Shares. Such Shares have been accepted for payment and will be promptly paid for in accordance with the terms of the tender offer. Following completion of the tender offer, CoreRx completed the acquisition of Societal CDMO through the previously planned second-step merger under Section 321(f) of the Pennsylvania Business Corporation Law of 1988. As a result of the merger, Societal CDMO became a wholly owned subsidiary of CoreRx. The common stock of Societal CDMO will be delisted from the Nasdaq Capital Market.

10:00 EDT Douglas Dynamics falls -6.2% - Douglas Dynamics is down -6.2%, or -$1.50 to $22.50.

10:00 EDT Bausch Health falls -6.4% - Bausch Health is down -6.4%, or -67c to $9.74.

10:00 EDT Ducommun rises 17.6% - Ducommun is up 17.6%, or $8.56 to $57.14.

09:51 EDT Adlai Nortye Ltd (ADR) trading resumes

09:47 EDT Ducommun rises 17.3% - Ducommun is up 17.3%, or $8.42 to $57.00.

09:47 EDT Amer Sports falls -4.4% - Amer Sports is down -4.4%, or -68c to $14.66.

09:47 EDT Kenon falls -5.4% - Kenon is down -5.4%, or -$1.24 to $21.55.

09:36 EDT Redwoods Acquisition Corp trading resumes

09:31 EDT Redwoods Acquisition Corp trading halted, volatility trading pause

09:30 EDT Adlai Nortye Ltd (ADR) trading halted, volatility trading pause

09:28 EDT Gain Therapeutics appoints Gene Mack as CFO - Gain Therapeutics announces the appointment of Gene Mack, MBA as its CFO, effective as of April 8, 2024. Prior to joining Gain, Gene was CFO at privately held Imcyse SA between 2021 and 2023.

09:23 EDT VivoPower unit Tembo met all milestones for follow-on strategic investment - VivoPower International is pleased to announce that its subsidiary Tembo has now met all the milestones to obtain the final follow-on strategic direct equity investment into Tembo, at a pre-money valuation of $120M. This is pursuant to a commitment received in June 2023 from a UAE based private investment office backed by a member of the ruling Al Maktoum family of Dubai. The investor, under the agreement terms, can exercise the option to increase its cumulative investment in subsequent closings, up to $10M based on milestones which have now all been met. VivoPower will continue to retain its majority stake in Tembo. Tembo recently announced a binding heads of agreement to execute a business combination agreement with CCTS, a NASDAQ listed SPAC at an indicative pre money equity valuation of $838m.

09:22 EDT U Power up 65% at $7.75 after announcing launch of EV battery swapping system

09:19 EDT Studio City Finance announces tender offer for up to $100M of senior notes - Studio City Finance has initiated a cash tender offer for up to an aggregate principal amount of $100M of its outstanding 6.000% senior notes due 2025. The Tender Offer is being made upon and is subject to the terms and conditions set out in the Offer to Purchase, dated April 8, 2024. The Tender Offer will expire at 5:00 p.m., New York City time, on May 6, 2024, unless extended or terminated by Studio City Finance. Tenders of the Notes may be withdrawn at any time at or prior to 5:00 p.m., New York City time, on April 19, 2024, but may not be withdrawn thereafter except in certain limited circumstances where additional withdrawal rights are required by law. The consideration for each $1,000 principal amount of Notes validly tendered on or prior to 5:00 p.m., New York City time, on April 19, 2024, and accepted for purchase will be $1,000, which includes an early tender premium. The consideration for each $1,000 principal amount of Notes validly tendered after the Early Tender Date and on or prior to the Expiration Time and accepted for purchase will be $970. Notes will be accepted only in minimum denominations of $200,000 and integral multiples of $1,000 in excess thereof. The Notes may be subject to proration if the aggregate principal amount of the Notes validly tendered would cause the Maximum Tender Amount to be exceeded. The settlement for Notes validly tendered on or prior to the Early Tender Date and accepted for purchase is expected to occur on April 24, 2024 . The settlement for Notes validly tendered following the Early Tender Date but on or prior to the Expiration Time and accepted for purchase is expected to be May 8, 2024. If the Tender Offer is fully subscribed as of the Early Tender Date, holders who validly tender Notes following the Early Tender Date will not have any of their Notes accepted for payment unless Studio City Finance increases the Maximum Tender Amount.

09:14 EDT Tracon Pharmaceuticals announces 1-for-20 reverse stock split - TRACON Pharmaceuticals announced that, following stockholder approval at the special meeting of stockholders held on September 6, 2023 of a proposal authorizing the board of directors of the Company to amend the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock at a ratio in the range of one-for-five to one-for-twenty, the Company's Board today approved a reverse stock split of the Company's common stock at a ratio of one-for-twenty. The effective time of the reverse stock split is 5:00 p.m. ET on April 9, 2024. Shares of the Company's common stock will begin trading on a split-adjusted basis commencing upon market open on April 10, 2024. As a result of the reverse split, each 20 shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value $0.001 per share, and there are now approximately 2.6 million shares of common stock issued and outstanding. The shares of the Company's common stock will trade under a new CUSIP number, 89237H308, effective April 10, 2024, and continue to be listed on the Nasdaq Capital Market under the symbol "TCON". All stock options and warrants of the Company outstanding immediately prior to the reverse stock split have been proportionally adjusted.

09:13 EDT Melco Resorts Finance announces proposed senior notes offering - Melco Resorts Finance proposes to conduct an international offering of senior notes, the net proceeds from which will be used to make a partial repayment of the principal amount outstanding under the revolving credit facility, together with accrued interest and associated costs, pursuant to a senior facilities agreement entered into by MCO Nominee One Limited, a subsidiary of Melco Resorts Finance, on April 29, 2020, and for general corporate purposes. Melco Resorts Finance is a wholly-owned subsidiary of Melco Resorts & Entertainment Limited. The New Notes are proposed to be senior obligations of Melco Resorts Finance, ranking equally with all of Melco Resorts Finance's existing and future senior indebtedness. Melco will not be a guarantor of the New Notes . The interest rate and other terms of the New Notes will be determined at the time of pricing of the offering. Completion of the proposed offering of the New Notes is subject to market conditions and investor interest. As no binding agreement in relation to the proposed offering of the New Notes has been entered into as at the date of this press release, the proposed New Notes may or may not be issued.

09:12 EDT Melco announces extension of maturity date of revolving credit facilities - Melco Resorts & Entertainment announces that the maturity date of its HK$14.85B revolving credit facility has been extended from April 29, 2025 to April 29, 2027. The 2020 Credit Facilities were originally established pursuant to a senior facilities agreement dated April 29, 2020, entered into between, among others, MCO Nominee One Limited, a subsidiary of Melco, as borrower, and Bank of China Limited, Macau Branch as agent, and was amended and restated pursuant to an amendment and restatement agreement dated June 29, 2023, to include the term Secured Overnight Financing Rate as a benchmark rate for loans denominated in U.S. dollars. The extension was made pursuant to a second amended and restated facility agreement dated April 8, 2024. Key terms such as facility size, pricing and financial covenants remain unchanged. In connection with the 2024 Amendment and Restatement Agreement, MCO Nominee One agreed to pay a customary fee to the consenting lenders.

09:10 EDT Booz Allen, Cloudfare now delivering rapid incident response - Cloudflare (NET) announced a collaboration with Booz Allen Hamilton (BAH), to support enterprises under attack by providing expedited Under Attack as a Service with 30-Day Rapid Response DDoS Mitigation, including continuous monitoring and protection. Under this new agreement, Booz Allen's Global Commercial clients facing a cyber attack will be connected to Cloudflare for immediate Incident Response. Now, Booz Allen clients that may fall victim to cyber attacks have a fast track to support when they need it most. "Cloudflare is known for being able to stop the largest cyber attacks in the world. We stand ready, now working with Booz Allen, to onboard and work hand-in-hand with organizations for immediate protection during the most pressing times," said Mark Anderson, President of Revenue, Cloudflare. "Across the commercial sector, we are seeing attacks increase as threat vectors expand. Whether a domain is down, or the client is facing ransomware, any business under attack can rely on us for rapid response and mitigation."

09:08 EDT Bango, NHN Corporation agree to wind down NewDeep Limited JV - Bango and NHN Corporation, the two shareholders of the NewDeep Limited joint venture have agreed that it is in the best interests of both shareholders to wind down the joint venture. And, to transfer the technology developed in the joint venture to Bango and NHN so both can use it without restriction in their respective core businesses.

09:05 EDT Beacon adds service in Atlantic Canada, Minneapolis markets - Beacon announced that it has opened new locations in Dieppe, New Brunswick, Canada and Spring Lake Park, Minnesota to serve residential and commercial roofing contractors. The new branch in Dieppe, New Brunswick will serve the Atlantic Canada region. "We are pleased to add service in our seventh Canadian province. Construction is on an upswing in this market due to population growth and our branch is well positioned to provide a strong catalog of both residential and commercial roofing products. Contractors will appreciate our team's knowledge and service commitment to help them grow their businesses," commented Charles Michaud, Beacon's Regional Vice President, Canada.

09:04 EDT Palladyne AI changes ticker symbol to PDYN - Palladyne AI announced that effective as of the market open today, April 8, 2024, the Company's ticker symbols have changed from Nasdaq: STRC and STRCW to Nasdaq: PDYN and PDYNW. The Company's intent to adopt the new ticker symbols was previously announced on March 18, 2024 when it announced its name change to Palladyne AI Corp. from Sarcos Technology and Robotics Corporation. "The updated PDYN ticker symbol is the latest step as part of our pivot to focus our business on our novel AI software platform that is intended to enable stationary and mobile robots to perform tasks that previously couldn't be automated or that required human intervention," said Ben Wolff, President and CEO. "Our Edge AI software platform enables robots to reason in a manner similar to humans, using far less training time, data and power than today's state-of-the-art deep learning methods, while learning and performing complex tasks that incorporate variations in the environment and objects being manipulated."

09:03 EDT Data I/O announces major milestone with 500th PSV system sale - Data I/O Corporation announced the Company has achieved a major milestone with the sale of the 500th PSV automated programming system. This milestone is a testament to Data I/O's continued innovation, investment, and leadership in programming technology for the automotive, industrial and consumer markets and signifies the PSV family as the most successful automated programming system in the industry. "Rapidly changing silicon technology, growing file sizes, increasing security requirements, and the connected smart factory create unique programming challenges for electronics manufacturers, threatening their ability to keep up with production demands. Our customers need a trusted programming platform that can grow and meet their ever-changing requirements. The PSV family helps them address these challenges," said Anthony Ambrose, President and CEO at Data I/O Corporation. "Data I/O's dedication to continuous innovation enables our customers to maximize their programming performance to meet these ever-increasing production requirements. Because of our substantial, ongoing investment and our upgrade strategy for PSV systems in the field, customers can leverage their existing Data I/O programming technology for years to come to achieve the lowest total cost of ownership."

08:58 EDT Collective Audience to acquire DSL Digital, terms not disclosed - Collective Audience entered into a definitive agreement to acquire DSL Digital, a provider of Marketing-as-a-Service solutions powered by proprietary AI technology. For Collective Audience, the acquisition is expected to form the foundation of a new AudienceServices group. Founded in 2019, DSL Digital has been providing digital performance advertising and marketing services to select global brands, including a market leader in enterprise application software and a Global 500 multinational professional services company. For these premier clients, the marketing services have included executing thousands of campaigns across hundreds of countries and involving multi-million dollar advertising spend. DSL Digital utilizes a proprietary set of AI-powered performance advertising tools to simultaneously run hundreds of performance advertising campaigns to continually improve performance metrics and outperform industry benchmarks. Collective Audience plans to productize DSL Digital's tool sets and integrate them with the existing modules in the company's AudienceCloud platform. DSL Digital's 20-member team, based in the U.S., Canada and Europe, is expected to join Collective Audience upon completion of the acquisition and lead the integration. Collective Audience anticipates the acquisition to generate significant revenue and positive EBITDA, and be consummated in an all-stock transaction according to the definitive acquisition agreement. The transaction is expected to close before the end of the current quarter.

08:57 EDT Jaguar Health granted extension to regain Nasdaq compliance - Jaguar Health announced that on April 5, 2024 the Company received formal notice that the Listing Qualifications Staff of The Nasdaq Stock Market has granted Jaguar an additional grace period, through August 13, 2024, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. To evidence compliance, the Company must report a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days on or before August 13, 2024. Jaguar's paramount near-term clinical activity is the Company's Phase 3 pivotal OnTarget trial of crofelemer for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea. Top line results from this pivotal study are forthcoming. The Company's common stock will continue to trade on Nasdaq under the symbol 'JAGX' pending the ultimate decision of any appeal process, and Jaguar's board remains committed to taking all required steps to remain in compliance with Nasdaq's listing standards.

08:54 EDT Entera Bio publishes data on oral PTH peptide tablet for osteoporosis in JBMR - Entera Bio Ltd announced that data from the Phase 2 Trial of its lead clinical compound, EB613 Oral PTH Tablets for the Treatment of Post-Menopausal Women with Low BMD or Osteoporosis compared to placebo were published in the Journal of Bone and Mineral Research JBMR .Miranda Toledano, CEO of Entera, commented, "We are excited to share that data from our successful Phase 2 study of EB613 has been accepted and now published in the prestigious JBMR. We believe EB613 addresses the current treatment gap in osteoporosis as the first oral, osteoanabolic bone building once-daily tablet treatment due to its unique format and potential dual mode of action. We remain highly committed to moving EB613 forward to meet the needs of patients."We conclude that this PTH tablet might be the first effective orally administered bone building medication and should be studied further in treatment of women with osteoporosis.

08:52 EDT Captivision enters partnership with Framework - Captivision announces a partnership with Framework and a prominent entertainment and streaming service partner to bring an immersive experience to the Framework in the Desert afterparty in Coachella Valley during the upcoming festival weekend. Captivision will deliver a unique media glass installation over three nights from Friday, April 12 through Sunday, April 14. The strategic partners are creating a revolutionary experience through Captivision's innovative media glass installed on modified freight containers. This collaboration marks the inception of a new area of strategic focus for Captivision dedicated to pushing boundaries and redefining the live entertainment experience. The Captivision installation will play digital content from the entertainment partners and Framework including art, trailers, and advertisements throughout the Framework in the Desert event at the Atlantic Aviation airport hangar in Thermal, California. Framework in the Desert, a renowned festival afterparty featuring top electronic music artists, is expected to generate over 80,000 physical impressions and over 1,000,000 social impressions through the weekend.

08:50 EDT Coherus data show CHS-1000 acts to reverse myeloid suppression - Coherus BioSciences presented preclinical data for its immuno-oncology pipeline candidate, CHS-1000, a novel ILT4 monoclonal antibody, at the 2024 AACR Annual Meeting being held in San Diego, California. Data presented show CHS-1000 is a potent monoclonal antibody that binds selectively to human ILT4 also known as LILRB2 with high affinity, efficiently blocking interaction with its ligands and reversing immunosuppressive functions, leading to activation of human dendritic cells and T cells and promoting polarization of macrophages to an inflammatory M1 phenotype. "Myeloid cell-mediated immunosuppression in the tumor microenvironment is a major contributor to tumor immune invasion and PD-1 resistance. The data presented in this poster demonstrate the potential for CHS-1000 to reverse myeloid suppression and activate an inflammatory immune response. The CHS-1000 IND submission is planned for Q2 2024

08:46 EDT Roper Technologies appoints John Murphy to board of directors - Roper Technologies (ROP) announced that John F. Murphy has joined the Company's Board of Directors. Murphy most recently served as Executive Vice President and Chief Financial Officer of Adobe (ADBE).

08:42 EDT Smart for Life to acquire Purely Optimal Nutrition, terms not disclosed - Smart for Life has executed a definitive agreement to acquire Purely Optimal Nutrition, a premier eCommerce nutraceuticals company with operations in North America. "This acquisition is another validation of our 'Buy-and-Build' strategy designed to establish Smart for Life as a major international force in the Health & Wellness sector," stated Darren Minton, CEO of Smart for Life. "We could not be more excited to extend our offering to include Purely Optimal's broad product line, which includes dozens of high-quality supplements. Purely Optimal is currently generating estimated revenue in excess of $8 million and over $1 million of Adjusted EBITDA for the trailing twelve months. In addition, the favorable impact and synergies with our manufacturing operations cannot be overstated. The Purely Optimal management team has created a world class brand with a deep and loyal customer base. We believe that Smart for Life can help further support and monetize that customer base with some substantial brand extensions, particularly in the area of the creation of Purely Optimal nutritional food products, formulated and manufactured at our FDA certified facility." The acquisition is expected to close within the next eight weeks and is subject to financing and customary closing conditions.

08:41 EDT KULR Technology receives award to supply SafeCASEs to eVTOL company - KULR Technology Group announces a significant expansion in the application of its proprietary and patented SafeCASE technology. KULR has received an initial award to supply SafeCASES to a leading electric vertical take-off and landing company. This partnership underscores the versatility and efficacy of SafeCASE in ensuring the safe handling and transport of batteries across sophisticated production facilities. The contract with this eVTOL manufacturer not only signifies a pivotal shift towards innovative applications of SafeCASE, but also marks KULR's organic growth trajectory through the burgeoning electric aviation sector. Initially developed for the safe transport of damaged, defective, and recalled batteries to recyclers, SafeCASE is now set to transform and facilitate how batteries are stored during the engineering and production processes in large commercial manufacturing settings.

08:38 EDT Luckin Coffee files audited 2023 financial statements - Luckin Coffee has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission.

08:37 EDT Vodafone, Infinite Reality showcase AI-Onboard at Mobile World Congress - Infinite Reality in partnership with Vodafone showcased its groundbreaking automotive original equipment manufacturer onboarding service, AI-Onboard, at the recent Mobile World Congress 2024 in Barcelona. The full service is expected to launch in the summer of 2024, marking the first stage of a strategic partnership between iR and Vodafone. Mobile World Congress, which ran from February 26-29, 2024, is an annual trade show and one of the world's largest telecommunications, connectivity and technology events. MWC 2024 was attended by over 100,000 delegates, including the King of Spain, and served as a global platform for iR and Vodafone to unveil AI-Onboard. At the event, the AI-Onboard platform, built using capabilities from Vodafone's new platform Pairpoint, was given its first look, captivating hundreds of daily visitors with its demo and its potential to transform the automotive retail landscape. As one of the 23 innovative divisions of Vodafone showcased at the event, Pairpoint stood out with its cutting-edge technology, setting a new benchmark for the industry and quickly became one of the highlights of the event.

08:35 EDT 1847 Holdings to acquire commercial cabinet maker - The company announced: "1847 Holdings LLC announced the execution of a non-binding Letter of Intent to acquire a large, established millwork, cabinetry and door manufacturer based in Las Vegas, NV. The Las Vegas-based target generated approximately $28.6 million in revenues, approximately $4.5 million in net income and approximately $5.2 million in adjusted EBITDA in 2023 and currently has almost a year's worth of contracted backlog booked for 2024. The purchase price for this transaction is $16.75 million and is expected to be completed during the third quarter of 2024, subject to the negotiation and entry into a definitive purchase agreement and the satisfaction or waiver of customary closing conditions. The proposed acquisition carries a purchase price of 3.2x 2023 EBITDA, and the Company expects to finance the entire transaction using debt."

08:35 EDT Loop Media announces partnership with Adnimation to increase CTV ad revenue - Adnimation and Loop Media announced a new partnership. The partnership has already yielded incremental revenue for both companies since it began. This partnership allows Loop Media to enjoy Google's premium demand while still looking to maintain its existing demand to maximize competition and increase fill rates and CPMs across the Loop CTV network.

08:34 EDT Blackstone to take AIR Communities private for $39.12 per share in cash - Blackstone (BX) and Apartment Income REIT (AIRC), or AIR Communities, announced that they have entered into a definitive agreement under which Blackstone Real Estate Partners X will acquire all outstanding common shares of AIR Communities for $39.12 per share in an all-cash transaction valued at approximately $10 billion, including the assumption of debt. The purchase price represents a premium of 25% to AIR Communities' closing share price on the NYSE on April 5, 2024, the last trading day prior to the announcement of the transaction, and a 25% premium to the volume weighted average share price on the NYSE over the previous 30 days. The transaction was unanimously approved by the AIR Communities Board of Directors and is expected to close in the third quarter of 2024, subject to approval by AIR Communities' stockholders and other customary closing conditions. As a condition to the transaction, AIR has suspended payment of its quarterly dividend, effective immediately.

08:32 EDT Biora Therapeutics announces patent covering BioJet liquid jet delivery tech - Biora Therapeutics announced the issuance of a new patent related to the company's BioJet platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The United States Patent and Trademark Office has issued U.S. Patent No. 11,938,295 entitled, "Ingestible Device for Delivery of Therapeutic Agent to the Gastrointestinal Tract." The issued claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract, including the stomach or small intestine.

08:31 EDT Amarin highlights key data on mechanistic insights into eicosapentaenoic acid - Amarin Corporation highlighted three data presentations at ACC.24 showcasing the mechanistic activity of Eicosapentaenoic acid, including the potential effects of EPA on endothelial cell dysfunction and on oxidation of samples enriched with Lp(a). The studies and their key findings are outlined below: Eicosapentaenoic acid and a High Intensity Statin Enhanced Expression of Proteins for Detoxification of Reactive Oxygen Species during Angiotensin II Challenge in Endothelial Cells This analysis measured the separate and combined effects of EPA and rosuvastatin on expression of proteins involved in detoxification in vascular endothelial cells under inflammatory conditions with angiotensin II. The combination of EPA and rosuvastatin favorably modulated the expression of proteins related to oxidative stress and detoxification under disease-like conditions. These findings indicate that the net benefits of a high intensity statin and EPA, compared to statin alone, on expression of detoxification proteins during inflammation may contribute to reduced atherothrombotic risk in outcome trials. Eicosapentaenoic Acid and Rosuvastatin Modulate Expression of Endothelial Proteins that Regulate Function and Platelet Activity during Angiotensin II Stimulation In this analysis, investigators compared the separate and combined effects of EPA and rosuvastatin on expression of proteins that regulate platelet signaling and nitric oxide levels in human umbilical vein endothelial cells subjected to angiotensin II stimulus. The combination of EPA and rosuvastatin favorably modulated proteins involved in platelet degranulation and NO bioavailability in HUVECs under inflammatory conditions to a greater extent than their separate treatments. The beneficial effects of a high intensity statin and EPA on endothelial dysfunction may contribute to reduced atherothrombotic risk in outcome trials. Eicosapentaenoic Acid Inhibits Lipoprotein(a) Oxidation due to Scavenging Mechanisms In Vitro Elevated Lp(a) levels are an independent and causal risk factor for cardiovascular disease with limited treatments available. Oxidized Lp(a) stimulates foam cell formation, endothelial dysfunction, and inflammation. In this analysis, investigators tested EPA effects on oxidation of samples enriched with Lp(a) compared to the fully saturated eicosaenoic acid and Trolox, a water-soluble analog of Vitamin E. Investigators found that EPA inhibited oxidation of Lp(a) enriched plasma in a time-dependent fashion consistent with a free radical scavenging mechanism. The potent antioxidant actions of EPA may contribute to reduced CV events in REDUCE-IT, including among those subjects with elevated Lp(a).

08:30 EDT Xinwu District in China announces pledge of support for LOBO EV - LOBO EV Technologies announced it received a pledge of support from the Xinwu District government in Jiangsu Province. This support, announced at a gala dinner celebrating LOBO's successful Nasdaq IPO, underscores the Company's role in spearheading the global electric mobility revolution from its base in Wuxi...Huajian Xu, CEO of LOBO, stated, "Our successful IPO on the Nasdaq marks not just a milestone for LOBO but a testament to our commitment towards innovation and excellence in the electric vehicle industry. Our guiding principles-Multi-model offerings, Quick delivery, Outstanding design and quality, coupled with cost Savings -are more than just a business strategy; they are a reflection of our dedication to meeting the evolving needs of our global customers while maintaining high standards of efficiency and affordability. This pledge of support from the Xinwu District government is a crucial step in our journey, empowering us to further innovate, expand, and lead the way in sustainable transportation solutions worldwide."

08:27 EDT GD Culture Group unveils short film 'Forgotten Planet' - GD Culture Group and its subsidiary, AI Catalysis unveil their latest venture into the convergence of art and AI technology with the debut of the captivating short film "Forgotten Planet" on the AI Catalysis website and social media platforms including Instagram, YouTube, X/Twitter, and LinkedIn, on April 5, 2024. The short film combines captivating storytelling with AI-generated video technology, aiming to push the boundaries of creativity and innovation in the filmmaking industry. "Forgotten Planet" transports viewers to the year 2079 AD, 110 years after mankind's first lunar landing. The gripping narrative follows Astronaut Mark, stranded on an enigmatic alien world following a catastrophic space mission failure.

08:24 EDT Rush Street Interactive appoints Brian Sapp as CMO - Rush Street Interactive announced the appointment of Brian Sapp to the newly-created role of Chief Marketing Officer. In his role as CMO, Brian brings a wealth of experience and a proven track record in leading data-driven marketing and live operations within the mobile industry and joins the Company's executive leadership team reporting directly to Richard Schwartz, Chief Executive Officer.

08:23 EDT Genetic Technologies, Humanise Health launch 'Know Your Risk' event - Genetic Technologies Limited announced an innovative partnership between GTG, and Humanise Health launching a "Know Your Risk" event featuring the company's unique Risk Assessment portfolio, to be held at The Langham, Pasadena, California on the 21st of May. This unique gathering is dedicated to empowering women by providing them with the knowledge and tools necessary for proactive management of their health, with a special focus on the advancements in genomics and personalised health strategies beyond the well-known BRCA1/2 genes.

08:21 EDT Ligand announces new topiramate injection data - Ligand Pharmaceuticals Incorporated presented new data on Captisol-enabled Topiramate Injection, a potential replacement therapy for the treatment of certain emergent neurological conditions, including epilepsy, when oral administration is not feasible. The poster was featured at the 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference in London, England. The authors presented modeling and simulations of IV topiramate dosing based on previous studies conducted by UMN faculty in healthy research participants and patients. In addition, preliminary pharmacokinetic data was presented from 25 healthy participants in a CURx ongoing randomized, single-center, open-label, cross-over clinical study for an investigational intravenous formulation of topiramate, an antiseizure and anti-migraine medication.

08:19 EDT INmune Bio presents data on INB03's role as immune check point - INmune Bio is presenting data on the use of INB03, a dominant-negative tumor necrosis factor TNF inhibitor of soluble TNF sTNF in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer TNBC . INB03 is shown to decrease T cell and macrophage immune checkpoint proteins PD1, TIGIT, LAG3, CD47 and SIRPa in a model immunotherapy resistant HER2+ breast cancer and decrease the metastatic potential of TNBC by downregulating cell surface markers of tumor invasion . The two posters will be presented at the annual American Association of Cancer Research in San Diego on April 8, 2024."Dr. Schillaci has shown that MUC4 expression in high-risk breast cancer subtypes is a predictor of resistance to therapy due to an unfavorable immunobiology of the TME and increased metastatic potential that is driven by soluble TNF," said RJ Tesi M.D., CEO of INmune Bio. "Neutralization of soluble TNF changes a resistant tumor biology into one that is more favorable. All of the individuals involved in this project share the belief that prospectively determining MUC4 expression in high-risk breast cancer subtypes will guide therapy decisions and significantly impact patient outcomes."

08:16 EDT TScan Therapeutics appoints Chrysta Louis M.D CMO - TScan Therapeutics announced the appointment of Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer. Dr. Louis has extensive experience in hematology and oncology drug development, with a track record of success in clinical development, medical affairs, and commercialization. "We are excited to welcome Chrystal to TScan at this critical time as we continue to progress both clinical-stage programs in heme malignancies and solid tumors. Chrystal's expertise, spanning all phases of drug development from Phase 1 studies to commercialization and life-cycle management, will be invaluable at this stage of rapid growth for the Company," said Gavin MacBeath, Ph.D., Chief Executive Officer. "I look forward to working with Chrystal as we strive to realize the full potential of our pipeline. On behalf of our Board and our team, I would like to thank Dr. Debora Barton for her key contributions that have enabled us to deliver positive data from our heme program and initiate our solid tumor program."

08:13 EDT Ameresco begins construction of biogas cogeneration project in California - Ameresco announced it entered a nearly $140M contract to develop and construct an advanced technology biogas cogeneration facility for the Sacramento Area Sewer District located at the EchoWater Resource Recovery Facility near Elk Grove, California. This on-site renewable energy facility will beneficially utilize biogas, a byproduct of the EchoWater Facility's solids treatment process, to produce renewable electricity and heat for the EchoWater Facility through an integrated 13.4 MW cogeneration plant that will utilize fuel cell and engine technology. By incorporating the fuel cell system, the project will have exceptional efficiency and reduced pollutant emissions, making it a clean, reliable baseload dispatchable resource. Additionally, the system will allow for the expandability to produce hydrogen in the future.

08:13 EDT Oryzon Genomics announces FDA clearance of IND to initiate Phase I/II trial - Oryzon Genomics announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application to initiate a Phase I/II trial with iadademstat plus immune checkpoint inhibitors in first line small cell lung cancer patients with extensive disease. This will be the first clinical trial testing the combination of iadademstat with immune checkpoint inhibitors. The trial is entitled "A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined With Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer". This Phase I/II clinical study will be conducted and sponsored by the National Cancer Institute, part of the National Institutes of Health, where Dr. Noura Choudhury from the Memorial Sloan Kettering Cancer Center will be the main PI for this trial and will be implemented by a number of prestigious cancer centers in the US, including the MSKCC, the JHU Sidney Kimmel Comprehensive Cancer Center and many others. The trial plans to enroll 45-50 patients and will be carried out under a Cooperative Research and Development Agreement that Oryzon has in place with the NCI.

08:12 EDT The Czechoslovak Group reviews benefits of planned acquisition of Kinetic Group - The Czechoslovak Group issued a statement reaffirming its commitment to the proposed all-cash acquisition of Vista Outdoor Inc.'s Sporting Products business - recently renamed The Kinetic Group - for a total consideration of $1.91 billion, with fully committed financing from leading U.S. bank JP Morgan Chase. CSG also highlighted the benefits of its planned Acquisition: "CSG is a leading industrial technology company operating across strategic business segments including defense, aerospace, ammunition and mobility. Under the leadership of current CEO and 100% owner Michal Strnad, CSG has become the pre-eminent Czech industrial group and built an extensive global footprint. We have a demonstrated history of supporting the long-term growth of our portfolio companies. We look forward to successfully closing the Acquisition of The Kinetic Group and becoming the steward of such venerable American brands as Federal, CCI and Remington. "

08:10 EDT FuelCell, EMTEC update, extend joint development agreement - FuelCell Energy (FCEL) and ExxonMobil Technology and Engineering Company (XOM) have updated and extended a joint development agreement governing the companies' development of unique technology that captures CO2 emissions directly from industrial sources while producing electricity and hydrogen simultaneously. As a result, access to the technology could be accelerated for commercial customers. The JDA between FuelCell Energy and EMTEC has been extended through December 31, 2026, to allow for continued development work for the technology, including support of the pilot project at the Esso Nederland BV Rotterdam Manufacturing Complex. The pilot project is co-funded by the European Union under the Emissions Trading System Innovation Fund and by the Netherlands Enterprise Agency by means of a Demonstration Energy and Climate Innovation grant. The agreement allows FuelCell Energy to incorporate elements of the jointly developed technology into existing carbon capture products currently being marketed to customers. This is expected to accelerate delivery of the technology to the market while the next generation cell and module design is being demonstrated in Rotterdam. The jointly developed carbon capture fuel cell technology to be demonstrated in Rotterdam features an optimized design for large scale installations. The technology, which captures carbon while simultaneously generating electricity and hydrogen, could improve the economics of carbon capture and could potentially lower the barrier to broader adoption of carbon capture in the marketplace. The JDA extension provides FuelCell Energy the opportunity to pursue carbon capture opportunities with customers using the optimized carbon capture cell architecture within our current generation module design incorporating select improvements derived from our joint development work. We believe this will accelerate delivery of the benefits of the technology to market while the next generation cell and module design are being demonstrated in Rotterdam. In addition, it will support future pioneer project deployments of the jointly developed technology that the companies anticipate pursuing with select customers. Along with the execution of the JDA extension, FuelCell Energy and ExxonMobil intend to negotiate a commercial framework aimed at enabling deployments of the carbonate fuel cell technology for carbon capture. In addition, FuelCell Energy and ExxonMobil will continue engaging the industrial emitter market, with a focus on demonstrating the unique value proposition offered by the ability to capture CO2 emissions from an external source and produce electricity and hydrogen simultaneously. Manufacturing of the modules for the Rotterdam demonstration has begun in FuelCell Energy's Torrington, Connecticut, manufacturing facility.

08:08 EDT Align Technology launches integrated consumer campaign - Align Technology announced the "Better Way" new advertising campaign for the Invisalign brand featuring the "Invis is for Kids" tagline and hashtag. "As part of our 'Invis is for Kids' strategy to improve the orthodontic experience for children, we are excited to launch the 'Better Way' integrated consumer campaign to drive awareness of how the Invisalign Palatal Expander System is a game-changer for expanding a child's narrow palate," said Kamal Bhandal, Align Technology vice president, Global Brand and Consumer Experience. "By sharing authentic experiences from parents whose kids have been treated by the Invisalign Palatal Expander System, as well as the first-hand experiences of patients and their doctors, our goal is to explain the benefits of the Invisalign Palatal Expander System as the product of choice for palatal expansion, through professional marketing material for doctors' offices and digital media content to reach moms across social media, TV, email, and digital."

08:07 EDT Boundless Bio presents preclinical data on BBI-355 - Boundless Bio presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy, BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research Annual Meeting 2024. BBI-355 is a novel, oral, selective inhibitor of checkpoint kinase 1 being studied in the ongoing, first-in-human, Phase 1/2 POTENTIATE clinical trial in patients with oncogene amplified cancers. "Extrachromosomal DNA afford unique advantages to tumors, typically rendering existing therapies ineffective and correlating with poor patient outcomes," said Chris Hassig, Ph.D., Chief Scientific Officer of Boundless Bio. "Our first poster presented this year at AACR demonstrated that BBI-355 overcame ecDNA-mediated targeted therapy resistance in preclinical tumor models by leveraging the enhanced reliance of ecDNA-driven tumor cells on CHK1 for survival. BBI-355 showed substantial antitumor activity, including complete and durable regressions, in preclinical oncogene amplified models.

08:07 EDT Chipotle announces partnership with TEKKEN 8 - Chipotle Mexican Grill announced its partnership with TEKKEN 8, the latest installment of the legendary fighting game franchise from Bandai Namco Entertainment America. Chipotle will give TEKKEN 8 players the opportunity to earn in-game currency through digital entree purchases made on the Chipotle app and Chipotle.com. In addition to the in-game currency offer, Chipotle is launching a new digital menu item inspired by TEKKEN fans, featuring TEKKEN 8 as the title game for the 2024 Chipotle Challenger Series, and serving as the presenting partner of the 2024 Evolution Championship Series.

08:06 EDT CytomX Therapeutics doses first patient in CX-2051 Phase 1 study - CytomX Therapeutics announced the first patient has been dosed in a Phase 1 dose escalation study of CX-2051 in patients with advanced solid tumors. CX-2051 is a masked PROBODY antibody drug conjugate directed toward epithelial cell adhesion molecule, a cell-surface target that is highly expressed across many cancer types including colorectal, gastric, endometrial, and ovarian cancers. The cytotoxic payload utilized in CX-2051 is a derivative of camptothecin, a topoisomerase-1 inhibitor, a class of drug that has shown potent clinical anti-cancer activity and demonstrated significant clinical benefit as an approved ADC in multiple cancers. The CX-2051 Phase 1 dose escalation is designed to efficiently test the safety and preliminary anti-tumor activity of CX-2051, to provide initial clinical proof of concept to inform a potential decision to move into dose expansions in 2025.

08:05 EDT The Oncology Institute appoints Jordan McInerney as CDO - The Oncology Institute announced the appointment of Jordan McInerney as the new Chief Development Officer, effective April 1, 2024. In this role, Mr. McInerney will spearhead growth initiatives for The Oncology Institute across diverse markets, including cultivating new partnerships with payors, driving M&A processes for acquisition targets, and establishing MSO platforms to deliver value-based oncology care nationwide. Bringing over 15 years of healthcare leadership, McInerney most recently served as the COO of HOPCo Network Solutions, a subsidiary of Healthcare Outcomes Performance Co.

08:04 EDT Aire Networks deploys Infinera's ICE-X coherent pluggable solution, no terms - Infinera announced that Aire Networks, a subsidiary of Grupo Aire, deployed Infinera's software-programmable ICE-X coherent pluggable solution to expand the capacity of its single-fiber network infrastructure across Spain and Portugal. The ability of Infinera's innovative ICE-X solution to provide ultra-high-speed transmissions over a single fiber in a pluggable form factor enables Aire Networks to continue to meet the bandwidth demands of its customers while maintaining its cost-effective single-fiber infrastructure. Aire Networks is a wholesale telecommunications operator with a network that spans over 33,000 kilometers, operating in Spain and Portugal, covering 90% of the territory and providing connectivity, voice, mobile virtual network enabler media, cloud, and data center solutions to local and regional operators as well as enterprise customers throughout the country.

08:04 EDT Digital Ally enters multi-year agreement with Kansas City Chiefs - Digital Ally announced the signing of a multi-year agreement with the Super Bowl Champion Kansas City Chiefs. The deployment includes 120 FirstVu PRO body cameras, two QuickVu 24-bay docking stations, as well as the utilization of Digital Ally's EVO Web cloud platform.

08:03 EDT Supernus: FDA says SPN-830 NDA 'not ready for approval' in present form - Supernus Pharmaceuticals announced a regulatory update for SPN-830. SPN-830 is an investigational apomorphine infusion device for the continuous treatment of motor fluctuations in Parkinson's disease under U.S. Food and Drug Administration review. The FDA has issued a Complete Response Letter in response to the Company's New Drug Application for SPN-830. The CRL indicates that the review cycle for the application is complete, but that the application is not ready for approval in its present form. The CRL mentions two areas that require additional review by the FDA or additional information to be provided to the FDA. The first area relates to product quality. The Company recently submitted additional product quality data to the FDA which it has not yet reviewed. The second relates to the master file for the infusion device which is proprietary to the device manufacturer. The Company plans to discuss with the device manufacturer the provision of the requested information and the steps required for the resubmission of the NDA for SPN-830. No clinical safety or efficacy issues were identified as a requirement for approval. The FDA completed in February 2024 a successful preapproval inspection of the device manufacturer's facility.

08:02 EDT Cognyte appoints Shvili, Sagiv to board of directors - Cognyte Software announced that two new members will join its Board of Directors effective as of May 1, 2024. Cognyte believes that Ron Shvili and Sarit Sagiv will bring additional expertise to the Board. They will replace Karmit Shilo and Zvika Naggan, who will be stepping down after three years as directors effective as of May 1, 2024. Shvili was previously Executive Vice President and Chief Technology, IT and Innovation Officer at Phoenix Holdings. Sagiv currently serves as a member of the Investments Committee of Phoenix Insurance.

07:47 EDT BioRestorative partners with Galen Patient Recruitment for BRTX-100 trial - BioRestorative Therapies announced a collaboration with Galen Patient Recruitment, which, combined with the recent expansion of clinical trial capacity from approximately 10 to 30 participants per month, is expected to help accelerate the completion of patient enrollment in the ongoing Phase 2 study of BioRestorative's lead clinical candidate, BRTX-100, in chronic lumbar disc disease. BRTX-100 is a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. The safety and efficacy of BRTX-100 in treating cLDD is being evaluated in a Phase 2, prospective, randomized, double-blinded and controlled study. A total of up to 99 eligible subjects will be enrolled at up to 16 clinical sites in the United States. Subjects included in the trial will be randomized 2:1 to receive either BRTX-100 or placebo.

07:35 EDT Iris Energy: Poolside upsizes and extends AI cloud cervices contract - IREN or Iris Energy provided a business update.Key Highlights: Previously announced 3-month AI cloud services agreement with leading AI company, poolside; Agreement is now upsized from 248 to 504 NVIDIA H100 GPUs following successful initial deployment; Additional 4-month term commencing mid-April 2024, and extension option for a further 2 months at the customer's election; IREN has upsized and extended its AI cloud services agreement with poolside, more than doubling the contracted cluster size from 248 to 504 NVIDIA H100 GPUs. The contract is for an additional 4-month term commencing mid-April, 2024, with an extension option for a further 2 months at the customer's election. Eiso Kant, CTO and Co-Founder of poolside, commented: "We've been very impressed with the outperformance of IREN's NVIDIA H100 GPU cluster as it sits amongst the best-in-class in reliability and performance, as well as the IREN team's commitment to customer support. Our business has growing demand for GPU compute and we're pleased to expand our partnership with IREN to support our growth."

07:33 EDT Venus Concept announces Israeli regulatory approval for Venus Bliss MAX - Venus Concept has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health. The Venus Bliss MAX was first launched commercially in the United States in Q1 2022 after FDA 510(k) clearance and offered internationally in approved jurisdictions. The Venus Bliss MAX offers three advanced technologies in one platform: diode laser applicators, (MP)2 applicator that combines Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields with advanced VariPulse technology and the Company's FlexMax EMS applicators. This advanced three-in-one platform enables practitioners to offer treatments for non-invasive lipolysis of the abdomen, flanks, back, and thighs, relief of muscle aches and pain, relief of muscle spasms, improvement in blood circulation, reduction in the appearance of cellulite and for muscle conditioning to stimulate healthy muscles.

07:30 EDT Gilat Satellite expanding into additional IFC market segments - Gilat Satellite Networks solutions, and services, announced that a leading IFC Service Provider is expanding its In-Flight Connectivity IFC capabilities with a strategic multimillion-dollar order mainly for Gilat's Taurus Aero modems. Taurus is an ultra-high-performance modem solution for In-Flight Connectivity IFC already deployed globally across tens of commercial airlines. Taurus delivers all satellite communication needs for multi-orbit constellations and Very High Throughput Satellites VHT and enables the delivery of reliable, high-performance connectivity solutions to air travelers. "We are honored to have been selected once again to expand and upgrade mission-critical In-Flight Connectivity services," said Amir Yafe, VP of Mobility & Global Accounts at Gilat. "This selection underscores the trust and confidence that industry leaders place in Gilat's advanced satellite communication solutions. We look forward to continuing to drive innovation and deliver superior IFC experiences to aviation customers around the world."

07:26 EDT Ivanhoe Electric appoints Lara Sims as VP, health and safety - Ivanhoe Electric announced that Lara Sims will join the Company as the Vice President, Health and Safety commencing April 8th, 2024.Prior to joining Ivanhoe Electric, Ms. Sims established Sims 360, a consulting business based in Yerington, Nevada, focused on building and implementing adaptive Health and Safety frameworks for over twenty mines in the United States

07:23 EDT Blue Water Industries completes sale of certain operations to Martin Marietta - Blue Water Industries announced today it completed the sale of 20 active aggregates operations in Alabama, South Carolina, South Florida, Tennessee, and Virginia to Martin Marietta Materials for $2.05B in cash on April 5, 2024. Blue Water Industries and its affiliates will continue to operate its aggregates operations in North Carolina and central Florida, as well as its marine terminal business.

07:20 EDT Renalytix announces financing with expected size up to $4M - Renalytix announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS to DB Capital Partners Healthcare. The Fundraise was conducted by way of a securities purchase agreement between the Purchaser and the Company which consists of an initial tranche of 2,666,667 Ordinary Shares initially for an amount of $1.0 million with an optional subsequent tranche of Ordinary Shares at the option of the Purchaser. Both tranches are priced at $0.75 per NASDAQ ADS. The aggregate total amount for both tranches, if the option is fully exercised, is expected to be up to $4 million in total financing. The net proceeds of the Fundraise will be used to support commercial sales activity as the Company continues its Formal Sale Process, as previously announced. Highlights: The Fundraise comprises a $1 million registered direct offering of the Initial Tranche Shares at $0.75 NASDAQ ADS, and an optional subsequent tranche at the same purchase price, exercisable at the purchaser's option until April 17, 2024. The sale and purchase of the Initial Tranche Shares and, if applicable, the Subsequent Tranche Shares shall complete no later than 11 April 2024 and 19 April 2024, respectively. The net proceeds of the Fundraise will be used to support commercial sales activity and provide enhanced optionality as the Company continues its ongoing Formal Sale Process, as previously announced. Pursuant to the securities purchase agreement entered into between the Company and the Purchaser on 5 April 2024, the Purchaser may, upon notice to the Company to be given no later than 5:00 p.m. New York time on 17 April 2024, subscribe for an optional subsequent tranche of Ordinary Shares. The Subsequent Tranche Shares shall not be more than such number of Ordinary Shares that the directors of the Company are authorised to allot and issue on a non-pre-emptive basis as of the date of the Subsequent Tranche Notice under the existing authorities granted at the Company's Annual General Meeting held on 15 December 2023. Any additional funding to be raised from issuing and allotting Ordinary Shares or other securities above existing authorities available shall be subject to the Company securing further authorities to allot and issue on a non-pre-emptive basis through a general meeting. The completion of the sale and purchase of the Initial Tranche Shares is expected take place no later than 11 April 2024, subject to customary closing conditions. Upon Initial Closing, the Purchaser will hold 2,666,667 Ordinary Shares which is expected to be approximately 2.18% of the Company's then issued share capital without taking into account any Ordinary Shares which may be allotted and issued from the date hereof and until the First Closing.

07:18 EDT James River Group granted request for preliminary injunction against Fleming - James River Group announced that the Supreme Court, New York County, Commercial Division granted the Company's request for a preliminary injunction against Fleming Intermediate Holdings, a portfolio company of private equity sponsor Altamont Capital Partners, ordering Fleming to complete its acquisition of JRG Reinsurance Company on or prior to April 16, 2024. Frank D'Orazio, the Company's CEO, commented, "We are pleased that the Court has granted James River's request for a preliminary injunction, compelling Fleming to complete the acquisition of JRG Re in accordance with the Stock Purchase Agreement that the parties negotiated together and executed on November 8, 2023. We look forward to finalizing the transaction."

07:16 EDT Graphjet Technology building agricultural waste-to-graphite production site - Graphjet Technology announced it plans to build a commercial artificial graphite production facility in Nevada. This plant is expected to be a first-of-its-kind in the United States.The plant is expected to be capable of recycling up to 30,000 metric tons of palm kernel material equivalent - a widely abundant agricultural waste product in Malaysia - to produce up to 10,000 metric tons of battery-grade, artificial graphite per year. This level of production is expected to be able to support the production of enough batteries to power more 100,000 electric vehicles EVs per year. In addition to producing graphite, Graphjet's first commercial plant in Malaysia, which is on track to be commissioned in the second quarter of 2024, will process palm kernel shells into hard carbon, which will be shipped to Nevada. This eliminates a conversion step in Graphjet's production process, which would enable its Nevada facility to produce graphite more quickly. Graphjet is aiming to commission and begin production at the new facility in 2026.

07:15 EDT Pineapple Energy urges shareholders to vote for reverse stock split - Pineapple Energy encourages its shareholders to participate actively in the upcoming meeting of shareholders scheduled on April 12, 2024. The Board of Directors emphasizes the importance of this shareholders' vote, specifically urging for a positive vote FOR the reverse stock split and FOR the increase in authorized shares. If you have previously cast your vote against these proposals, we strongly recommend reconsidering your position and voting in favor of these proposals. Pineapple's management team is committed to growing leading local and regional solar, storage, and energy services companies nationwide. The Board believes that the reverse stock split and increase in authorized shares is instrumental for several reasons, including: Maintenance with Nasdaq Listing Status: If the Reverse Stock Split Proposal is not approved by the Company's shareholders, the Company's common stock may be delisted from Nasdaq. Maintaining a Nasdaq listing is crucial for investor confidence, potential investment inflows, and to maintain liquidity in the Company's common stock; and Increased Shares to Satisfy Conversion Obligations and for Potential Fundraising: The Company is obligated to maintain a required minimum reserve of at least 200% of the number of shares issuable upon conversion of the Series A convertible preferred stock and common stock warrants from the authorized shares of its common stock. Shareholders must approve the increase in authorized shares in order for the Company to have enough authorized shares to meet these obligations. In addition to satisfying its conversion obligations, additional authorized shares are needed to facilitate the Company's ability to conduct a successful fundraising effort. Failure to secure approval for the reverse stock split may hinder management's ability to execute its strategy, to the potential detriment of shareholders. Additionally, it may impede business development initiatives dependent on the issuance of common stock. A Nasdaq delisting could complicate shareholders' ability to trade the Company's common stock, impact its price and affect the shareholders' ability buy or sell when desired. It is essential to understand that a reverse stock split consolidates existing shares, preserving the Company's overall value and each shareholder's respective ownership percentage. Failure to increase the company's authorized shares will result in the Company being unable to meet its conversion obligations and will limit the Company's ability to conduct successful fundraising. The inability to conduct successful fundraising raises substantial doubt about the Company's ability to continue as a going concern.

07:13 EDT EchoStar's Hughes Network awarded contract from GA-ASI - Hughes Network Systems, an EchoStar company, announced its it has been awarded a production contract from General Atomics Aeronautical Systems to produce a key component of the next-generation satellite communications system for the MQ-1C Gray Eagle 25M Unmanned Aircraft System. Under the contract, Hughes will provide advanced, ruggedized HM400 modems, named the HM400T, that integrate with the DoD's standard waveform technology and transmission security features to enable significantly increased endurance and resilience for Gray Eagle 25M's wide range of Airborne Intelligence, Surveillance and Reconnaisance mission requirements, particularly for operations in contested environments.

07:11 EDT Ginkgo Bioworks, IdeeLab Biotechnology enter agreement - IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, announced that is has entered into an agreement with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, to join the Ginkgo Technology Network. The Ginkgo Technology Network is a groundbreaking global ecosystem of cutting-edge technology partners dedicated to driving innovation in customer R&D programs. Ginkgo plans to integrate the technological capabilities of its network partners to provide customers with more robust end-to-end solutions to drive successful R&D outcomes across biological end markets.

07:10 EDT NextCure and LCB present data on B7-H4 antibody drug conjugate at AACR - NextCure announced the presentation of new preclinical data on LNCB74, a B7-H4-targeting antibody drug conjugate ADC developed in partnership with LigaChem Biosciences LCB , formerly LegoChem Biosciences, , at the 2024 American Association for Cancer Research AACR Annual Meeting in San Diego, CA. The poster presentation highlights LNBC74's promising preclinical safety and anti-tumor activity. LNCB74 is an ADC utilizing LigaChem Biosciences' proprietary site-specific conjugation and plasma-stable, cancer selectively activating linker technology to link monomethyl auristatin E MMAE to a B7-H4 targeting antibody in a drug-to-antibody ratio of 4 DAR4 . The presentation includes data demonstrating LNCB74's high affinity and specificity for human B7-H4, a protein highly expressed on a range of solid tumors including breast, ovarian and endometrial cancers. "LNCB74 was developed through NextCure's expertise in B7-H4 tumor biology and LCB's ConjuAllTM technology, resulting in a potent ADC with initial data demonstrating excellent tolerability and pharmacokinetics," said Solomon Langermann, Ph.D., NextCure's chief scientific officer. "These data underscore that LNCB74 is a promising candidate for the treatment of a variety of solid tumor indications. We look forward to continuing our work building a robust preclinical dataset to further support advancing this ADC to the clinic."...LNCB74 was engineered for an improved safety profile and therapeutic index with increased stability in circulation, tumor selective payload release, and a reduction in off-target release of active payload, mitigating toxicity compared to traditional vedotin ADCs.

07:09 EDT Aris Mining names Richard Orazietti as CFO, effective May 16 - Aris Mining (ARMN) announces the appointment of Richard Orazietti as CFO, effective May 16, and Oliver Dachsel as Senior Vice President, Capital Markets. Orazietti was the CFO of Westport Fuel Systems (WPRT) from 2019 to 2022.

07:07 EDT Eyenovia considers strategic alternatives, including possible sale - Eyenovia announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia, MicroPine, and initiated a process to explore strategic alternatives to maximize shareholder value. As part of this process, the Company plans to consider a wide range of options, including potential sale of assets of the Company, a sale of the Company, a merger, or other strategic action. In conjunction with the strategic process and focus on its late stage MicroPine asset, Eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expenses while continuing to support meaningful value generation from the company's two FDA-approved products. ..."In the meantime, we will be evaluating strategic opportunities for MicroPine with organizations that have existing capabilities and infrastructure necessary to fully capitalize on this large opportunity. Additionally, we continue to make significant progress advancing our commercialization strategy, with Mydcombi and Avenova currently being sold through our targeted sales force, and clobetasol to be commercially launched as soon as this summer."..."However, we believe this progress, and the broader potential of MicroPine, which will be back in our hands in a matter of weeks, has been underrecognized and underappreciated by the financial markets. As a result, while we remain intently focused on laying a foundation for accelerating sales growth in 2025, we are in parallel reducing costs in areas that do not impact our ability to deliver on our core strategy and exploring a possible transaction or transactions that could generate capital or otherwise enhance value for our shareholders, who remain very supportive. I look forward to evaluating a comprehensive variety of alternatives with my fellow Board members in the coming weeks." ...Eyenovia is in the process of engaging with investment banks to assist with the evaluation. There can be no assurance that this process will result in the company entering or completing any transaction. Eyenovia does not intend to make any further disclosures regarding the strategic review process unless and until a specific course of action is approved.

07:05 EDT Tela Bio appoints Howard Langstein as VP, medical affairs, surgeon strategy - TELA Bio announced Howard Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy. Dr. Langstein is the former Chief of Plastic and Reconstructive Surgery at the University of Rochester Medical Center, known for his extensive expertise, especially in microvascular reconstruction and innovative approaches to complex surgical problems.

07:04 EDT Alkermes presents results from long-term safety study of LYBALVI - Alkermes announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International Research Society, which took place April 3-7, 2024 in Florence, Italy. Analyses were presented from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI in patients who received up to four years of treatment. LYBALVI is approved in the U.S. for the treatment of adults with schizophrenia, and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or as adjunct to lithium or valproate. Rene Kahn, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, presented the data in an oral presentation during the "New Pharmacological Treatments and Assessments" session. New analyses were presented related to the subset of participants in the study who reached at least two years of treatment and the subset of participants who reached four years of treatment, providing information as to the long-term safety profile and durability of treatment effect of LYBALVI at specific points in time. Key findings are as follows: Patient Disposition: 523 participants received at least one dose of LYBALVI in this global, open-label extension study. Depending on geography and enrollment date, patients had the opportunity to receive up to two to four years of treatment in this study. 188 (35.9%) participants completed the study, as defined in the protocol, having received between two to four years of treatment and attended their final study visit. There were 451 patients who had the opportunity to receive at least two years of LYBALVI treatment, of which 242 (53.7%) did so. There were 335 patients who had the opportunity to receive four years of LYBALVI treatment, of which 109 (32.5%) did so. Changes in Weight, Waist Circumference, and Metabolic Parameters: For patients who contributed data to the two-year assessment, mean change from baseline in body weight was 0.84 kg and waist circumference was -0.56 cm. For patients who contributed data to the four-year assessment, the mean change from baseline in body weight was 2.65 kg and waist circumference was 1.37 cm. In addition, there were minimal changes in lipid and glycemic parameters over the treatment period. Adverse Events: The adverse event profile of LYBALVI was consistent with previous studies. Overall, 60% of participants reported at least one AE. The most common AEs reported were weight increase, headache, anxiety, insomnia, somnolence, nausea and weight decrease. Most AEs were mild to moderate in severity. Symptoms: Patients' symptoms of schizophrenia or bipolar I disorder remained stable, as measured by the Clinical Global Impression of Severity scale. For patients who contributed data to the two-year assessment, mean change from baseline in CGI-S score was -0.18. For patients who contributed data to the four-year assessment, mean change from baseline in CGI-S was -0.24. According to Dr. Kahn, "The study results, which include data from patients who received up to four years of treatment on LYBALVI, demonstrated that the combination of olanzapine and samidorphan delivered long-term tolerability, including across key weight and metabolic parameters, and sustained symptom control, further reinforcing LYBALVI's potential utility as a foundational maintenance treatment option for people living with schizophrenia or bipolar I disorder."

07:01 EDT Bruker advances magnet technology for broader adoption of NMR - Bruker Corporation announces novel magnet technology and analytical solutions to support broad adoption of nuclear magnetic resonance, NMR, in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies, PAT.

06:55 EDT SolarBank to begin trading on Nasdaq Global Market on April 8 - SolarBank is pleased to announce the company's common shares will commence trading on the Nasdaq Global Market at opening of trading on Monday, April 8. The company's common shares will trade under the symbol "SUUN." The company's common shares will continue to trade on the Cboe Canada Exchange under the symbol "SUNN".

06:47 EDT BWX Technologies, Rolls-Royce awarded space reactor development project - BWX Technologies (BWXT) announced that it and Rolls-Royce (RYCEY) have secured funding for Phase 2 of the UK Space Agency's International Bilateral Fund. The funding enables strategic research collaborations within the UK space sector and emerging space nations to work together on fission nuclear systems for space power missions. The new $1.5M award from the fund supports collaboration between Rolls-Royce and BWXT Advanced Technologies to advance the technologies that benefit both the UK and U.S. space nuclear development programs.

06:37 EDT Aquaron Acquisition announces additional contribution to trust account - Aquaron Acquisition announced that Bestpath IoT Technology has deposited into the Company's trust account an aggregate of $70,000, in order to extend the period of time the Company has to complete a business combination for one additional month, from April 6, 2024 to May 6, 2024. The Company issued a promissory note to Bestpath with a principal amount equal to the amount deposited. The promissory note bears no interest and is convertible into the Company's shares of common stock at a price of $10.00 per unit at the closing of a business combination by the Company. The purpose of the extension is to provide more time for the Company to complete a business combination.

06:34 EDT Oculis announces 'positive' results from Phase 3 OPTIMIZE-1 trial of OCS-01 - Oculis Holding announced that Eric Donnenfeld, M.D., presented the positive results from the Phase 3 OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 ASCRS Annual Meeting, which took place April 5-8, 2024, in Boston, MA. Dr. Donnenfeld presented the "Once Daily OCS-01, an OPTIREACH Formulation of High Concentration Dexamethasone Eye Drop, for Inflammation and Pain Following Cataract Surgery - a Phase 3, Double-Masked, Vehicle-Controlled Study" on Sunday, April 7th. The results showed that 57.2% of patients treated with OCS-01 were inflammation free at Day 15, and 75.5% had absence of ocular pain at Day 4. Oculis initiated the second Phase 3 OPTIMIZE-2 trial with OCS-01 once daily eye drop in late 2023 and topline readout is expected before the end of 2024. The two Phase 3 OPTIMIZE trials are expected to support an NDA submission.

06:32 EDT Tradeweb Markets to acquire ICD for $785M - Tradeweb Markets announced it has entered into a definitive agreement to acquire Institutional Cash Distributors, an institutional investment technology provider for corporate treasury organizations trading short-term investments, for $785M, subject to customary adjustments. The purchase price is expected to be funded with cash on hand. Upon closing of the transaction, ICD's CEO Tory Hazard will report to Tradeweb President Thomas Pluta and will join Tradeweb's Operating Committee. The acquisition is expected to be accretive to Tradeweb's adjusted earnings per share in the first 12 months following closing and meet Tradeweb's return on invested capital objectives. Completion of the transaction is expected in the second half of 2024, subject to customary closing conditions and regulatory review.

06:26 EDT JPMorgan releases Chairman & CEO letter to shareholders - JPMorgan Chase & Co. has published its 2023 Annual Report, including letters to shareholders from its Chairman & CEO and other business heads. Reference Link

06:16 EDT UMC reports March revenue NT$18.17M, up 2.7% y/y - Reports January-March revenue NT$54.63M, up 0.78% y/y.

06:12 EDT Canoo announces partnership with Red Sea Global - Canoo announced its innovative electric vehicles will be used in a pilot program by Red Sea Global, the developer behind the regenerative tourism destinations The Red Sea and AMAALA. Red Sea Global will pilot Canoo's Lifestyle Vehicle, Lifestyle Delivery Vehicle 190, and the Bulldog pickup truck. The Canoo vehicles will be piloted for travel between Red Sea Global's international airport, its various resorts, facilities, and excursions. This trial will help tailor Canoo's zero-emission vehicles to RSG's use cases and mobility needs. Canoo's premium LV will provide transportation for guests traveling between Red Sea International Airport (RSI) and its resorts and residential properties. Likewise, Canoo's LDV 190 can help with the movement of guest luggage items between RSI and the various properties. Canoo's Bulldog fits the use case and needs of RSG's experience companies, Akun, WAMA, and Galaxea, for transporting guests to their various excursions.

06:10 EDT Savage Ventures signs two-year exclusive contract with Primis - Savage Ventures signed a two-year exclusive contract with Primis for American Songwriter. American Songwriter has been enriching the music community by assisting millions of music fans and songwriters in exploring the craft of music. In collaboration with Primis, American Songwriter has expanded its video distribution and brought a more relevant video experience to American Songwriter's audience.

06:08 EDT U Power to launch commercial operation for EV battery swapping system - U Power Limited announced that its battery-swapping and sharing model for two-wheeled and light four-wheeled electric vehicles is poised for a formal commercial rollout in Wuhu, Anhui Province, China. The rollout, which is expected to take place during April 2024, follows a successful round of market validations in February. As part of this expansion, U Power plans to establish 60 power-swapping service points which will cater to over 800 customers. The battery-swapping and sharing technology for two-wheeled and light four-wheeled EVs involves the use of identical battery cells and packaging methods. The battery packs for both types of EV are stored in a single battery-swapping station. When customers need to swap batteries, they can take one to two battery modules for two-wheeled EVs, or four to eight modules for light four-wheeled EVs. The battery-swapping process is straightforward and user-friendly, with the user verifying their identity at the BSS with their mobile phone and following a series of simple prompts to access and swap their batteries.

06:06 EDT CLEAR, American Express renew partnership to provide travel experiences - CLEAR (YOU) is extending its partnership with American Express (AXP) as the companies recommit to delivering premium value to Members and enhancing the airport experience. Amid ongoing high demand for air travel, this partnership allows eligible American Express Card Members who enroll in CLEAR and pay using their American Express credit cards to receive up to $189 in annual statement credits for their membership purchases. CLEAR Plus provides Members with a more predictable travel experience at airport checkpoints by allowing them to verify their identity with their eyes, fingerprints, or face and get directly to physical security before heading to their gate.

06:03 EDT KBR awarded $450M in support, services contracts from U.S. Government - KBR has been awarded new contracts estimated at more than $450 million to deliver highly technical systems engineering support and services to the U.S. Government. Under the terms of these contracts, KBR will provide systems engineering, acquisition support, phenomenology expertise and data science, as well as applied research, communications security infrastructure, operations and maintenance support

05:59 EDT Pharming Group completes enrollment in pediatric clinical trial of leniolisi - Pharming Group announces the completion of patient enrollment in its Phase III clinical trial evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta inhibitor, in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome. Leniolisib, marketed under the brand name Joenja in the U.S., received approval from the U.S. FDA for the treatment of APDS in adult and pediatric patients 12 years of age and older in March 2023. Pharming plans to include data from this 4-11-year-old trial in regulatory filings worldwide for the approval of leniolisib for pediatric patients with APDS, beginning in 2025.

05:55 EDT Accenture to acquire Climb, no terms disclosed - Accenture has agreed to acquire Climb, a technology services provider specializing in system integration, IT infrastructure management and operations, primarily in the Gunma Prefecture. The acquisition of Climb brings more critical skills for global organizations in Japan to navigate technology change. Completion of the acquisition is subject to customary closing conditions.

05:53 EDT Black Diamond Therapeutics presents preclinical data on BDTX-1535 at AACR - Black Diamond Therapeutics presented real-world evidence of the evolving epidermal growth factor receptor mutation landscape in non-small cell lung cancer, and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies. The results were disclosed in an oral presentation on April 7 at the 2024 American Association of Cancer Research Annual Meeting held in San Diego, California. The oral presentation, titled "BDTX-1535 - A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical and the C797S Resistance Mutation to Address the Evolved Landscape of EGFR Mutant NSCLC," evaluated more than 235,000 sequenced cases of NSCLC sourced from Guardant Health and Foundation Medicine. The analyses reveal a broad spectrum of non-classical mutations, as well as an increased prevalence of the acquired resistance mutation, C797S. Over 100 unique non-classical EGFR oncogenic driver mutations were identified in newly diagnosed patients with NSCLC, and these non-classical EGFR mutations were present in 20-30% of patients across all lines of treatment. Preclinical data demonstrated that BDTX-1535 potently inhibits more than 50 clinically relevant, non-classical EGFR mutations (as well as the classical L858R and exon19-del mutations) while sparing wild-type EGFR. The compound also potently inhibits the drug resistance C797S mutation, which emerges following treatment with third-generation EGFR inhibitors, including osimertinib. Real-world data indicate non-classical EGFR mutations can be co-expressed with classical mutation L858R, a setting that has been characterized by shorter duration of response to osimertinib first-line therapy. Preclinical data show that BDTX-1535 potently inhibits these co-expressed non-classical mutations. Phase 1 proof-of-concept data demonstrating durable responses in recurrent NSCLC patients with both non-classical and acquired resistance C797S mutations were presented in October 2023. Black Diamond is currently advancing BDTX-1535 in a Phase 2 trial for patients with EGFRm NSCLC across multiple lines of therapy. Patients are being enrolled both in a first-line setting (for those expressing EGFR non-classical mutations) and in second- and third-line settings following prior treatment with an EGFR inhibitor. Initial results from 2L/3L patients are anticipated in the third quarter of 2024.